Oligometastatic cervical cancer: definitive RT confers survival benefit

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Definitive radiation therapy (DRT) to limited sites in patients with oligometastatic cervical cancer (CC) yields favorable outcomes with potential long-term survival benefit.
  • At 2 y post-RT, approximately half of the patients had disease progression with minimal toxicity.

Why this matters

  • In patients with regional CC who progress to metastatic disease, systemic chemotherapy offers median survival of
  • Although chemotherapy is the current treatment of choice, DRT may be more effective and safe in this patient population.

Study design

  • Study of 38 patients with oligometastatic CC involving ≤2 extra-pelvic/para-aortic sites, receiving external-beam DRT and brachytherapy with concurrent chemotherapy or surgical resection..
  • Oligometastasis included synchronous (n=9) or metachronous (n=15) disease to supraclavicular nodes or recurrence in mediastinum (n=10), lung (n=7), or supraclavicular+mediastinal sites (n=3).
  • Median follow-up, 35.2 mo (range 3.1-94.7).
  • Funding: National Institute of Cancer.

Key results

  • Median OS was 50.7 mo (95% CI, 36.8-64.6 mo); 2- and 3-y OS rates were 73.5% and 63.7%, respectively.
  • 18 and 6 patients had survived >3 and >5 y, respectively.
  • Median PFS was 21.7 mo (95% CI, 5.6-37.8 mo).
  • 55% patients progressed; median time to progression was 24.8 mo (95% CI, 5.0-44.6 mo).
  • Treatment-associated grade ≥3 toxicity was

Limitations

  • Highly selected and small study population.